Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGI-F705 in Parkinson's Disease
NCT07647614Phase 2Not yet recruiting
- Sponsor
- Energenesis Biomedical Co., Ltd.
- Start
- Dec 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
A Phase 2 trial of ENERGI-F705 in Parkinson's disease (PD), sponsored by Energenesis Biomedical Co., Ltd.. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ENERGI-F705
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07647614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647614.